RAD001 and ZOledronic acid in Renal cell carcinoma patients with bone metastases (RAZOR) ??? a randomised phase II trial

Author: Hinder, Victoria; Broom, RJ; Pollard, S; Sharples, K; Fong, P; Hanning, F; Deva, S; Forgeson, G; Jameson, Michael; O'Donnell, A; Harris, D; North, R; Grey, A; Findlay, Michael

Date: 2011

Publisher: The Authors

Type: Conference item

Link to this item using this URL: http://hdl.handle.net/2292/18917

The University of Auckland Library


Bone metatases from renal cell carcinoma are common, destructive and have been identified as an adverse prognostic feature, even in the modern targeted therapy era.

Citation: ["New Zealand Society of Oncology, Auckland, 12 May 2011 - 13 May 2011."]

Copyright: https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm